Strong IP keeps collaboration alive, allowing companies to attract capital, strike partnerships, and bring innovations to patients, according to legal experts at Ice Miller.

Tom Wells at 4C Associates, explores the future of biologistics, or how the packaging, storage, and logistics for biologics ...

Leadership means knowing when to jump in and when to let someone else worry about the details, writes Hope Mueller, SVP of Corporate Development and Strategy at Currax Pharmaceuticals.

On this week's episode of the Business of Biotech, Anthony Japour, M.D., CEO at iTolerance, talks about his work as a physician treating infectious diseases, his CEO role in diagnostics at the height ...

Part one of a two-part series on FDA Commissioner Martin Makary, M.D.s comments at the Gailen Forum in New York City on October 30, 2025.

Women leaders are driving success in life sciences but remain underrepresented and undervalued. That needs to change, writes ...

On this week's Business of Biotech episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Science Leader's ...

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

The well-worn adage “good companies are bought, not sold” suggests that top-tier businesses, especially in high-growth industries like life sciences, do not need to seek buyers; instead, buyers pursue ...

Failure to comply with clinical trial disclosure regulations poses risks that extend far beyond potential fines or reputational damage for sponsors. In the context of mergers and acquisitions (M&A), ...

The Greenphire Clinical Finance suite addresses longstanding inefficiencies in clinical trial financial management. Oncology studies often face negotiations exceeding 100 days, delaying patient access ...